Drug Trial Radar · NCT05490030
Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants
Last checked: Nov 19, 2026Latest source record: Feb 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Mar 6, 2025
Primary completion
Jun 26, 2025
Study completion Jun 26, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- Collaborators
- Pharmaceutical Research Associates
- First posted
- Aug 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of various degrees of hepatic impairment on plasma pharmacokinetics (PK), safety and tolerability of TNO155. The results of this study will guide the Novartis recommendation regarding whether or not a dose adjustment may be needed when treating patients with hepatic impairment.
Conditions
- Hepatic Impairment
Interventions
TNO155Drug
Single oral dose of TNO155 on Day 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-versus-time curve (AUC) from time zero to the last measurable plasma concentration (AUClast) of TNO155Time frame: Up to 240 hours post single dose
- AUC from time zero to time "t" (AUC0-t) of TNO155Time frame: Up to 240 hours post single dose
- AUC from time zero to infinity (AUCinf) of TNO155Time frame: Up to 240 hours post single dose
- Maximum (peak) observed plasma concentration (Cmax) of TNO155Time frame: Up to 240 hours post single dose
- Time to reach maximum observed plasma concentration (Tmax) of TNO155Time frame: Up to 240 hours post single dose
- Elimination half-life (T1/2) of TNO155Time frame: Up to 240 hours post single dose
- Sampling time of the last measurable plasma concentration (Tlast) of TNO155Time frame: Up to 240 hours post single dose
- Apparent plasma clearance (CL/F) of TNO155Time frame: Up to 240 hours post single dose
- Apparent volume of distribution during terminal phase (Vz/F) of TNO155Time frame: Up to 240 hours post single dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.